Nintedanib treatment for bleomycin-induced lung injury - First report
Although the antineoplastic agent bleomycin is known for more than 50 years, its exact pharmacological and side-effect mechanisms remain incompletely understood. The major limitation of bleomycin therapy is the risk of pulmonary toxicity which can be diverse, and potentially fatal in 10% of patients...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2023-01-01
|
| Seri Bilgileri: | Respiratory Medicine Case Reports |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2213007123001168 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|